AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 23665671
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml normal saline with 1:200,000 epinephrine per tonsil (Group 1)
Trial: 23665671
Drug: 3 ml
RxNorm normalized name: WATER,INHL 3 ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 ml 1% lidocaine with 1:200,000 epinephrine per tonsil (Group 2)
Trial: 23665671
Drug: 8 ml
RxNorm normalized name: ethanol 0.8 ML/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 8 ml normal saline with 1:200,000 epinephrine per tonsil (Group 3)
Trial: 21131668
Drug: 17.4 mg/24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 17.4 mg/24 h rivastigmine patch
Trial: 19484917
Drug: rivastigmine capsule
RxNorm normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: rivastigmine capsule (3 to 6 mg twice-daily)
Trial: 6377997
Drug: Daily streptomycin,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily streptomycin, isoniazid, rifampin, and pyrazinamide for 12 months
Trial: 6377997
Drug: Selective chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective chemotherapy (antituberculosis chemotherapy not started until disease confirmed active)
Trial: 30325658
Drug: GH antagonist
RxNorm normalized name: Interleukin-1 receptor antagonist anakinra
DrugBank: Anakinra (DB00026)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: GH antagonist treatment
Trial: 10655953
Drug: Inulin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inulin (10 g daily)
Trial: 1987105
Drug: Timolol maleate
RxNorm normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Timolol maleate 0.5% ophthalmic solution, 1 drop twice daily for 14 days
Trial: 418431
Drug: Pimozide tablets
RxNorm normalized name: Pimozide Tablets
DrugBank: Pimozide (DB01100)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pimozide tablets
Trial: 394794
Drug: Fluphenazine decanoate
RxNorm normalized name: Fluphenazine Decanoate
DrugBank: Fluphenazine (DB00623)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluphenazine decanoate injections
Trial: 31831042
Drug: Preoperative concurrent
RxNorm normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Preoperative concurrent chemoradiotherapy (n=104)
Trial: 19222614
Drug: Levodopa therapy
RxNorm normalized name: Levodopa
DrugBank: Levodopa (DB01235)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Levodopa therapy alone
Trial: 17406754
Drug: IFN 3
RxNorm normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IFN 3 MU daily + ribavirin 1.0‐1.2 g daily for 12 weeks followed by IFN 3 MU thrice weekly + ribavirin 1.0‐1.2 g daily for 48 weeks (IFN QD)
Trial: 12793140
Drug: Captopril (capoten)
RxNorm normalized name: Captopril
DrugBank: Captopril (DB01197)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Captopril (capoten) 25‐75 mg/day for 4 weeks
Trial: 12793140
Drug: Benazepril (lotensin)
RxNorm normalized name: benazepril Oral Tablet [Lotensin]
DrugBank: Benazepril (DB00542)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Benazepril (lotensin) 5‐30 mg/day for 24 weeks
Trial: 7778148
Drug: Paracetamol given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol given 2 h after quinine (n = 7)
Trial: 7778148
Drug: Paracetamol given
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol given 2 h before quinine (n = 7)
Trial: 2212378
Drug: Intracoronary infusion
RxNorm normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intracoronary infusion of Fluosol-DA 20%
Trial: 31927748
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous methylprednisolone (4.5 g cumulative dose during 12 weekly infusions)
Trial: 18674978
Drug: Individualized pressure
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Individualized pressure ulcer education and monthly structured telephone follow-up (n=20)
Trial: 18674978
Drug: Monthly mail
RxNorm normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Monthly mail or telephone follow-up without educational content (n=11)
Trial: 19200542
Drug: Rosuvastatin 40
RxNorm normalized name: rosuvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rosuvastatin 40 mg/day
Trial: 10403866
Drug: 1.2 ml
RxNorm normalized name: Mozobil 24 MG in 1.2 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.2 ml 0.5% bupivacaine (6 mg)
Trial: 10403866
Drug: 3.4 ml
RxNorm normalized name: ALCOHOL 43.4 mL in 70 mL TOPICAL GEL [Dr. HANDs Gel]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.4 ml 0.18% hypobaric bupivacaine (6.1 mg)
Trial: 2333740
Drug: Follow-up formula
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up formula with 1.5 g protein/dl (2.0 g/kg/d)
Trial: 2333740
Drug: Follow-up formula
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up formula with 2.2 g protein/dl (3.0 g/kg/d)
Trial: 2333740
Drug: Follow-up formula
RxNorm normalized name: Q-Up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Follow-up formula with 2.9 g protein/dl (3.7 g/kg/d)
Trial: 2333740
Drug: Formula only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Formula only (15 g/dl)
Trial: 6999291
Drug: Probucol (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probucol (1000 mg/day)
Trial: 23642941
Drug: Everolimus (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Everolimus (10 mg)
Trial: 19076108
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Pregabalin + Dexamethasone
Trial: 19076108
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Pregabalin
Trial: 19076108
Drug: Paracetamol +
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Paracetamol + Placebo
Trial: 3898440
Drug: Ceftriaxone (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ceftriaxone (1 gram preoperative dose)
Trial: 3898440
Drug: Cefazolin (three
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefazolin (three 1 gram parenteral doses over a 16 hour period)
Trial: 24641678
Drug: levodopa 0.76
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa 0.76 mg/kg with 25% carbidopa
Trial: 24641678
Drug: levodopa 0.51
FDA approved: no
EMA approved: no
PMDA approved: no
Description: levodopa 0.51 mg/kg with 25% carbidopa
Trial: 18823469
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg ketorolac i.v. after induction of anaesthesia
Trial: 18823469
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg etoricoxib orally as premedication
Trial: 12460706
Drug: Hydrochlorthiazide (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorthiazide (12.5 mg/day)
Trial: 10783990
Drug: New developments
FDA approved: no
EMA approved: no
PMDA approved: no
Description: New developments in chemotherapy
Trial: 1345755
Drug: Lowest zidovudine
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lowest zidovudine dose alone (regimen 6)
Trial: 1345755
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with zidovudine and ddC at the doses tested
Trial: 1345755
Drug: Daily oral
RxNorm normalized name: GEMTESA 75 MG Once-Daily Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily oral dose of 150 mg of zidovudine
Trial: 6735963
Drug: Oltipraz administered
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz administered under fasting conditions (25 mg/kg)
Trial: 6735963
Drug: Oltipraz administered
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz administered with a low fat meal (less than 5% fat)
Trial: 6735963
Drug: Oltipraz administered
RxNorm normalized name: Oltipraz
DrugBank: Oltipraz (DB12539)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oltipraz administered with a high fat meal (24% fat)
Trial: 8679366
Drug: Morphine 0.2
RxNorm normalized name: morphine 0.23 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine 0.2 mg
Trial: 21644105
Drug: Fentanyl 25
RxNorm normalized name: FENTANYL 25MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 25 µg
Trial: 21644105
Drug: Fentanyl 12.5
RxNorm normalized name: FENTANYL 12.5MCG/HR PATCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl 12.5 µg plus Morphine 0.1 mg
Trial: 16491208
Drug: Fixed combination
RxNorm normalized name: Progestogens and estrogens, fixed combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fixed combination of amlodipine and losartan
Trial: 12794792
Drug: Intravenous doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous doxycycline
Trial: 3129362
Drug: rIFN-gamma (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma (0.5 mg)
Trial: 3129362
Drug: rIFN-gamma (all
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN-gamma (all doses)
Trial: 17891897
Drug: Caffeine (CAF)
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Caffeine (CAF) 200 mg
Trial: 29449791
Drug: Placebo (PLA)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (PLA) 200 mg dextrose
Trial: 27723543
Drug: High-dose curcumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose curcumin extract (500mg b.i.d.)
Trial: 23199378
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (autograft or lumbar disc treatment)
Trial: 15531489
Drug: r-metHuLeptin (0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: r-metHuLeptin (0.05 mg/kg sc daily)
Trial: 11579010
Drug: Tandospirone (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tandospirone (30 mg/day)
Trial: 7968119
Drug: Amoxycillin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxycillin (500 mg three times daily for 7 days)
Trial: 8141211
Drug: Erythromycin (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (500 mg four times daily for 7 days)
Trial: 3475663
Drug: Placebo injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo injections of saline solution
Trial: 20524068
Drug: MedCoat coated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MedCoat coated divided non-flavoured placebo tablets
Trial: 3822503
Drug: Low osmolar
RxNorm normalized name: Watersoluble, nephrotropic, low osmolar X-ray contrast media
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low osmolar (LO) compound
Trial: 3822503
Drug: High osmolar
RxNorm normalized name: Watersoluble, nephrotropic, high osmolar X-ray contrast media
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High osmolar (HO) compound
Trial: 17563741
Drug: Consolidation chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Consolidation chemotherapy
Trial: 31586838
Drug: Repeated ketamine-assisted
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repeated ketamine-assisted ECT (group RK), ketamine at the dose of 0.3 mg/kg for each ECT treatment
Trial: 17011666
Drug: Intravenous progesterone
RxNorm normalized name: Progesterone
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intravenous progesterone
Trial: 9740462
Drug: 50 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m2 methotrexate alone
Trial: 27564555
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg (TT genotype patients)
Trial: 27564555
Drug: Ramosetron 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ramosetron 0.3 mg (non-TT genotype patients)
Trial: 27564555
Drug: Palonosetron 0.075
RxNorm normalized name: palonosetron 0.075 MG in 1.5 ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Palonosetron 0.075 mg (TT genotype patients)
Trial: 25286965
Drug: 1% lidocaine
RxNorm normalized name: Icy Hot Max 4%-1% Lidocaine Pain Relief Dry Topical Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1% lidocaine mixed with dexamethasone 2.5 mg
Trial: 11426093
Drug: 5g intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5g intravenous bolus of MgSO4
Trial: 9231547
Drug: Fixed-dose low
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed-dose low molecular weight heparin (LMWH) (Group II), 3500 units subcutaneous twice daily for a period of 5 days
Trial: 2141109
Drug: L-carnitine (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine (3 g orally daily)
Trial: 25777347
Drug: Chemotherapy (cisplatin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy (cisplatin and vinorelbine) without disulfiram
Trial: 24884848
Drug: Immediate loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate loading of a single mandibular midline implant with an overdenture
Trial: 24884848
Drug: Delayed loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed loading of a single mandibular midline implant with an overdenture
Trial: 16086839
Drug: Topical diclofenac
RxNorm normalized name: diclofenac Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical diclofenac solution (Pennsaid)
Trial: 26506138
Drug: Vehicle control
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vehicle control solution
Trial: 7624902
Drug: Oral hydrochlorothiazide
RxNorm normalized name: hydrochlorothiazide Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral hydrochlorothiazide
Trial: 6519165
Drug: Intravenous furosemide
RxNorm normalized name: Furosemide
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous furosemide
Trial: 6667629
Drug: Aqueous beclomethasone
RxNorm normalized name: Pen-Aqueous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aqueous beclomethasone dipropionate nasal spray (100 micrograms into each nostril twice daily for 14 days)
Trial: 6667629
Drug: Conventional pressurized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional pressurized spray
Trial: 29110681
Drug: Add-on treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Add-on treatment with mianserin
Trial: 29110681
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of mianserin and IRT
Trial: 22097195
Drug: CM comprehensive
RxNorm normalized name: Easy Care First Aid Kit - Comprehensive KIT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CM comprehensive regimen (intravenous dripping of Chinese herbal preparation, oral administration of Chinese herbal decoction, and point application)
Trial: 22097195
Drug: Single-agent maintenance
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-agent maintenance chemotherapy (control)
Trial: 26620049
Drug: Vildagliptin 50
RxNorm normalized name: vildagliptin 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin 50 mg bid
Trial: 19705345
Drug: Gliclazide up
RxNorm normalized name: gliclazide
DrugBank: Gliclazide (DB01120)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gliclazide up to 320 mg/day
Trial: 16622596
Drug: PEG‐IFN‐alpha treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN‐alpha treatment (6 microg/kg once a week for 8 weeks, then 3 microg/kg/week)
Trial: 30206088
Drug: apixaban 2.5
RxNorm normalized name: apixaban 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apixaban 2.5 mg twice daily
Trial: 22852870
Drug: Diclofenac SR
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac SR 75 mg BID plus omeprazole 20 mg daily
Trial: 9527752
Drug: Bromazepam (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromazepam (3 mg)
Trial: 28935219
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion pills dispensed by trained pharmacy workers in Makwanpur district (GROUP 2)
Trial: 28935219
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion pills dispensed by pharmacy workers in Chitwan district (GROUP 1)
Trial: 28935219
Drug: Medical abortion
RxNorm normalized name: ABSORPTION BASE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medical abortion pills dispensed by trained pharmacy workers in both groups
Trial: 18807578
Drug: Reference formulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference formulation of omeprazole (20 mg)
Trial: 25591469
Drug: Finerenone 1.25-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Finerenone 1.25-20 mg once daily
Trial: 20944049
Drug: Postdated delayed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postdated delayed prescriptions
Trial: 20944049
Drug: Usual delayed
RxNorm normalized name: HYDROGEN PEROXIDE 5 mg in 100 mL TOPICAL LIQUID [USUALKLENZ DISINFECTANTSPRAY]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual delayed prescriptions
Trial: 17974490
Drug: Nabilone (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nabilone (0.5 mg PO at bedtime to 1 mg BID over 4 weeks)
Trial: 11978292
Drug: Methotrexate (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methotrexate (50 mg/m²) followed by misoprostol (800 micrograms vaginally)
Trial: 11978292
Drug: Mifepristone (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mifepristone (600 mg) followed by misoprostol (400 micrograms orally)
Trial: 8526180
Drug: Sublingual immunotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sublingual immunotherapy with grass allergen extracts
Trial: 786689
Drug: Propranolol (640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (640 mg/day)
Trial: 26811130
Drug: Pea fiber
RxNorm normalized name: Pea fiber
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pea fiber (PF; 15 g/d)
Trial: 21297005
Drug: Medial collagen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medial collagen meniscus implant (MCMI)
Trial: 21434398
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of RF EMF exposure and monotonous activity
Trial: 11171650
Drug: Selective attenuation
RxNorm normalized name: varicella, live attenuated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective attenuation of gonadotropin‐releasing hormone feedforward signal intensity
Trial: 11171650
Drug: Selective augmentation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective augmentation of gonadotropin‐releasing hormone feedforward signal intensity
Trial: 9628521
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg leuprorelin acetate depot per month i.m. + 20 mg ethinyloestradiol + 0.15 mg desogestrel orally for 3 weeks (group A)
Trial: 9628521
Drug: 3.75 mg
RxNorm normalized name: zopiclone 3.75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.75 mg leuprorelin acetate depot per month i.m. + placebo (group P)
Trial: 18422741
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption <25 g/week
Trial: 18422741
Drug: Alcohol consumption
RxNorm normalized name: Alcohol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alcohol consumption 25-175 g/week
Trial: 12930169
Drug: L-carnitine L-tartrate
RxNorm normalized name: L-carnitine (free form) (as L-carnitine L-tartrate)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-carnitine L-tartrate (2 g per day)
Trial: 9110123
Drug: HMG-CoA reductase
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitors (fluvastatin, lovastatin, pravastatin, simvastatin)
Trial: 9110123
Drug: Simvastatin 17.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 17.3 mg/day or 20 mg/day
Trial: 28837593
Drug: Paliperidone palmitate
RxNorm normalized name: Paliperidone Palmitate
DrugBank: Paliperidone (DB01267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Paliperidone palmitate once-monthly
Trial: 15162916
Drug: Cardixin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cardixin (0.25 mg)
Trial: 861135
Drug: Lanoxin (0.25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lanoxin (0.25 mg)
Trial: 11641292
Drug: Pet ownership
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pet ownership with lisinopril (20 mg/d)
Trial: 11641292
Drug: Lisinopril (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lisinopril (20 mg/d) only
Trial: 2692407
Drug: 3‐day treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3‐day treatment of daily 2‐h infusions of 0.5 mg/kg in 250 ml of saline (group A)
Trial: 10492856
Drug: Maintenance ECT
RxNorm normalized name: Dental Resources Perio Maintenance Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance ECT combined with neuroleptic medication (Phase III study)